Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: WTDEC who wrote (19738)	4/28/1998 8:45:00 PM
From: John O'Neill	Read Replies (1) \| Respond to of 32384

WTDEC... I didn't mean to compare it to injectable cytokines..just the challenge in general. If STAT tech is harder to develop..all the better when LGND is successful. Zacks put this out today... MCDE 8.5625 2 + (upgraded) LGND 14.4375 2 No change ESTIMATE REVISIONS: LGND: HAMBRECHT&QUIST made new estimate for quarter ending 03/98 of $-0.13 on 04/06/98 MCDE: HAMBRECHT&QUIST has reiterated estimate for fiscal year ending 12/99 of $-0.04 on 04/23/98 MCDE: HAMBRECHT&QUIST made new estimate for quarter ending 03/98 of $-0.10 on 04/06/98 RECOMMENDATION CHANGES: LGND: BANCAM/ROB STEP changed recommendation from Strong Buy to Moderate Buy on 04/23/98